NXGL
NEXGEL, Inc.1.6400
+0.0500+3.14%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
13.35MP/E (TTM)
-Basic EPS (TTM)
-0.37Dividend Yield
0%Recent Filings
8-K
NexGel licenses Celularity biomaterials
NexGel signed an asset purchase and exclusive license agreement with Celularity on March 6, 2026, for its commercial-stage biomaterials portfolio including Biovance and Centaflex, plus development programs. Consideration totals up to $35.0 million in cash: $15.0 million upfront, $20.0 million in sales milestones. Closing targeted by April 15 hinges on financing; it grants exclusive rights outside Asia, with ancillary manufacturing and sublease deals. Deal exposes NexGel to supply risks from Licensor.
8-K
NexGel funds $1.8M acquisition
NexGel entered a securities purchase agreement on February 9, 2026, issuing $1.8M Series A senior secured convertible notes at 10% OID, funded February 10 for an approved acquisition by April 15. Proceeds locked under control agreement fund the deal; Series B up to $55M follows if closed, secured by all assets. Notes mature in two years with $1.244/share conversion, floor $0.249.
8-K
Interim CFO appointed
NexGel appointed Adam Drapczuk III as Interim CFO effective January 1, 2026, replacing Joseph McGuire whose employment ended December 31, 2025. Drapczuk, prior CFO until 2024 and recent consultant, gets $200,000 annual pay plus planned equity. McGuire separation details pending. Smooth transition taps familiarity.
8-K
NexGel spins off drug delivery
NexGel spun off its drug delivery program into NexGelRx on December 11, 2025, retaining a non-dilutive 19.99% equity stake up to $8 million in capital raises and a perpetual 5% global royalty on Rx sales. NexGel stays exclusive hydrogel manufacturer while NexGelRx chases prescription opportunities. Shareholders gain targeted upside. Forward-looking potential carries execution risks.
IPO
Website
Employees
Sector
Industry
BAX
Baxter International Inc.
19.05-0.48
NEPH
Nephros, Inc.
4.85-0.01
NUWE
Nuwellis, Inc.
2.21+0.03
NXL
Nexalin Technology, Inc.
0.81-0.01
RGNT
Regentis Biomaterials Ltd.
6.05-0.84
SSKN
Strata Skin Sciences, Inc.
1.33-0.03
TELA
TELA Bio, Inc.
1.18+0.05
TFX
Teleflex Incorporated
124.87-1.85
UEEC
United Health Products, Inc.
0.06+0.00
ZYXI
Zynex, Inc.
0.34-0.32